Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtake rival ...
Bristol-Myers Squibb’s drive to build its Opdivo immunotherapy franchise continues, this time with a new FDA filing to treat melanoma in an earlier setting. BMS has asked the FDA for a licence to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback